Navigation Links
Arable Corporation Announces New Technology for Clinical Trial Industry
Date:10/11/2010

PALO ALTO, Calif., Oct. 11 /PRNewswire/ -- Arable Corporation (www.arablecorp.com) has announced the launch of Arable Perform to bring unique CTMS technologies to the clinical trial industry.  Whereas traditional CTMS systems have been costly and require months to implement, Perform brings CTMS and EDC capabilities without the traditionally high start-up costs.

The Arable Perform platform allows Sponsors or CROs to manage the planning and implementation of multiple trials simultaneously.  Perform also provides large Sites with the ability to manage their service delivery to multiple CROs or Sponsors.  With Perform's proprietary dashboard, stakeholders and managers are able to view real-time status of trials down to the site or subject visit.

"Our new Arable Perform platform allows us to offer our clients immediate access to clinical trial software with the shortest "Go Live" time in the industry and at a reasonable cost," stated Ary Sarkar, CEO of Arable Corporation.  "At Arable, we combine our knowledge of the clinical trial space with our technology partnerships to offer our clients a range of services from trial planning and implementation through regulatory submittal."

Arable brings a suite of services to offer the pharmaceutical and biotech industries.  With the addition of the Perform platform, Arable introduces CTMS and EDC software to complement their existing partnerships with GlobalSubmit and Quest Life Sciences.

Arable is announcing a 30 day free trial of their Perform platform to highlight the benefits to clinical organizations.  With the economic recovery continuing to affect pharma and biotech R & D budgets, Arable believes that the Perform software will save clinical organizations money and increase time to market.  Terms and conditions apply to the free offer.

Arable Corporation combines the right technology with our proven CRO services to facilitate any size clinical trial.  Arable's Regulatory Services has partnered with GlobalSubmit, the leading name in eCTDs, whose products are used exclusively by the United States FDA and top pharmas worldwide.  Arable CRO Services brings the experience of over 50 research scientists from one of the most respected CROs in India, Quest Life Sciences Pvt. Ltd. Quest's record of accomplishment includes over 300 clinical trials, an FDA approved site, and a 22,000 square foot clinical facility.


'/>"/>
SOURCE Arable Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Results are in: Users of BodyMedias Wearable Body-Monitoring Technology Lose 3 Times More Weight
2. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
3. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
4. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
5. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
6. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
7. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
8. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2011 Earnings Release Date and Teleconference
11. Medical Simulation Corporation Signs Agreement With a Nationally Ranked Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 astic drugs ... type of antineoplastic drug aiming at functions at multiple ... in to a new stage. Download the ... there are nearly four million cases of new tumors ... aging of population, environmental pollution caused by industrialization and ...
(Date:2/22/2017)... YORK , Feb. 22, 2017 ... the atherosclerosis partnering deals and agreements entered into ... the full report: http://www.reportlinker.com/p03605675-summary/view-report.html Description ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
(Date:2/22/2017)... Summary Provides understanding and access ... entered into by the worlds leading healthcare companies. ... The Global Motor Neurone Disease Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... - Top deals by value - Deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... A cylindrical “pipeline” used ... harder to reach ones, according to the results of a clinical trial announced ... Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist Health and ...
(Date:2/22/2017)... ... February 22, 2017 , ... THR ... “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified CBD product utilizes Quicksilver ... the bloodstream. Far outpacing the absorption speed of all other products, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery ... available on the App Store and Google Play . Florida-based Sober ... addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management ...
(Date:2/22/2017)... ... 2017 , ... Bellus Medical, a leader in medical aesthetics, ... of Platelet Rich Plasma (PRP). PRP systems are used by physicians in areas ... and provide a faster and more efficient healing process. There are many systems ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of American respondents ... family members or friends have also commented about their poor hearing. However, only ... aids. One reason, suggested by 89 percent of American respondents, is that they ...
Breaking Medicine News(10 mins):